Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Anavex Life Sciences Corp.NASDAQ: AVXL

Accumulated OCI · Q1 FY2026 · quarter ended Dec 2025

Accumulated OCI remains negative

Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
Year agoDec 2024
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Accumulated OCI vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Accumulated OCI amounts to 0.0% of total assets for AVXL, versus a peer median of 0.3%.
AVXL Competitors
Accumulated OCI for AVXL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VALNValneva SEMar 2026€85.08M EUR+11.3%-9.7%22.8%
MGTXMeiraGTx Holdings plcMar 2026$2.58M USD+150.9%-26.4%1.1%
MLTXMoonLake ImmunotherapeuticsMar 2026$322K USD-86.5%+19.8%0.1%
ABSIAbsci CorporationMar 2026$304K USD+1500.0%—0.2%
CTMXCytomX Therapeutics, Inc.Mar 2026$102K USD+10300.0%+123.1%0.0%
AVXLAnavex Life Sciences Corp.Dec 2025$0 USD——0.0%
ARVNArvinas, Inc.Mar 2026-$400K USD-126.7%—0.1%
RGNXREGENXBIO Inc.Mar 2026-$870K USD-14.2%—0.3%
MBXMBX Biosciences, Inc. Common StockSep 2026-$1.96M USD-1371.4%+356.8%0.4%
ERASErasca, Inc.Sep 2026-$4.19M USD-744.8%—0.4%
Peer median (excluding AVXL) —-14.2%+19.8%0.3%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents152.11M149.16M151.02M132.19M102.58M
Short-term Investments00000
Net Receivables9.14M3.19M2.71M2.45M809K
Inventory16.37K0000
Other Current Assets(16.37K)162653K931K429K
Total Current Assets161.62M152.7M154.39M135.57M103.82M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets16.37K3.55B3.36M00
Total Non-current Assets16.37K3.55B3.36M00
Total Assets161.62M152.7M154.39M135.57M103.82M
Account Payables4.74M3.82M4.32M9.63M4.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue443.83K443.83K917K842K805K
Other Current Liabilities0(47)1.36M1.53M1.56M
Total Current Liabilities10.8M10.21M12.53M15.3M8.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities10.8M10.21M12.53M15.3M8.95M
Common Stock75.92K77.94K82K85K87K
Retained Earnings(197.59M)(245.56M)(293.07M)(336.07M)(382.45M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity150.82M142.49M141.85M120.26M94.87M
Total Debt00000
Net Debt(152.11M)(149.16M)(151.02M)(132.19M)(102.58M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.